United Therapeutics Corporation (NASDAQ:UTHR) Receives $646.00 Average PT from Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $646.00.

Several brokerages recently weighed in on UTHR. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America decreased their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $168,188,006.77. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 434,075 shares of company stock valued at $233,942,595 over the last quarter. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System lifted its position in United Therapeutics by 55,526.2% during the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares during the period. BlackRock Inc. purchased a new stake in United Therapeutics during the 2nd quarter valued at about $2,868,735,000. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Jupiter Topco LLC acquired a new position in shares of United Therapeutics in the second quarter valued at about $450,140,000. Finally, Norges Bank purchased a new position in shares of United Therapeutics in the fourth quarter worth about $293,418,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.0%

Shares of UTHR opened at $512.88 on Friday. The company has a 50 day moving average of $532.35 and a two-hundred day moving average of $538.04. United Therapeutics has a twelve month low of $302.19 and a twelve month high of $609.35. The company has a market cap of $22.00 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the firm posted $6.41 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics will post 26.33 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.